- Defibrotide improves Day+100 survival and complete response in patients with VOD and multi-organ failure compared with a historical control.
- The historical control selection methodology offers a novel approach for investigation of a life-threatening orphan disease.
Slingshot members are tracking this event:
Results from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online in BLOOD
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Feb 01, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3 Trial, Results, Severe Veno-occlusive Disease, Multi-organ Failure, Defibrotide, Vod, Sinusoidal Obstruction Syndrome, Post-hematopoietic Stem-cell Transplantation